Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in Pediatric Solid or CNS Tumors
NCT03690869Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2018
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of cemiplimab in solid tumor, central nervous system tumor, diffuse intrinsic pontine glioma (DIPG) and 1 more (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Treatment-emergent Adverse Events at 36 months, Severe Treatment-emergent Adverse Events at 36 months and 8 more. Started Sep 2018; status: terminated.
02
Drugs
cemiplimab
03
Conditions
solid tumorcentral nervous system tumordiffuse intrinsic pontine glioma (DIPG)glioma
Beyond the preview
Go deeper on NCT03690869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690869.